One of the approved BsAbs used in clinics is blinatumomab (MT103), a BiTE that binds to CD3/CD19 and that has been used for the treatment of relapsed or refractory (R/R) Philadelphia chromosome-negative or -positive B cell acute lymphoblastic leukemia (Ph −/+ B-ALL) and non-Hodgkin lymphoma (NHL) [15,32,45]. The gene discussed is CD19; the disease is non-Hodgkin lymphoma.